Epizyme Inc

Epizyme — J.P. Morgan 2018 Healthcare Conference

26 slides from Epizyme's conference presentation, Jan 8, 2018

  1. Slide 1: J.P. Morgan 2018 Healthcare Conference: Epizyme Company Overview

    Slide 1: J.P. Morgan 2018 Healthcare Conference: Epizyme Company Overview

    J.P. Morgan 2018 Healthcare Conference REWRITING TREATMENTS FOR PATIENTS WITH CANCER AND OTHER SERIOUS DISEASES EPIZYME COMPANY OVERVIEW Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS regulatory approvals to conduct trials or to market products; whether the Company’s cash resources will be sufficient to fund the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availabili

  3. Slide 3: Multiple Tazemetostat Accelerated Approval Opportunities

    Slide 3: Multiple Tazemetostat Accelerated Approval Opportunities

    MULTIPLE TAZEMETOSTAT ACCELERATED APPROVAL OPPORTUNITIES TAZEMETOSTAT POSITIVE INTERIM DATA IN SOLID TUMORS AND BLOOD CANCERS FIRST NDA SUBMISSION TARGETED FOR 2H 2018 FINANCIALLY STRONG BROAD PIPELINE ADDRESSING NOVEL EPIGENETIC TARGETS EXPERIENCED LEADERSHIP TEAM

  4. Slide 4: Focused on Our Vision

    Slide 4: Focused on Our Vision

    FOCUSED ON OUR VISION BUILD ROBUST CLINICAL PIPELINE WITH AT LEAST THREE NEW PRODUCT CANDIDATES IN DEVELOPMENT LAUNCH TAZEMETOSTAT GLOBALLY IN MOLECULARLY DEFINED SOLID TUMORS AND NON-HODGKIN LYMPHOMA EXPAND TAZEMETOSTAT INTO EARLY-LINE SETTINGS, COMBINATIONS AND NEW TUMOR TYPES FURTHER ESTABLISH OU

  5. Slide 5: A Transformational Year for Epizyme

    Slide 5: A Transformational Year for Epizyme

    A TRANSFORMATIONAL YEAR FOR EPIZYME FOLLICULAR LYMPHOMA Opened FL enrollment in US Presented interim Phase 2 data Accelerated EZH2 mutation enrollment Fully enrolled EZH2 wild-type cohort Engaged with regulatory authorities on registration path Granted Fast Track and Orphan Drug Designation DIFFUSE

  6. Slide 6: Tazemetostat Development Strategy Based on EZH2 Mechanism of Action

    Slide 6: Tazemetostat Development Strategy Based on EZH2 Mechanism of Action

    DIRECT DEPENDENCE ON EZH2 FUNCTION MONOTHERAPY TARGETED AGENT COMBO APPROACHES I/O COMBO APPROACHES OTHER ACTIVITIES B-CELL MATURATION TUMOR & IMMUNE PRIMING TAZEMETOSTAT DEVELOPMENT STRATEGY: BASED ON BROAD IMPLICATION OF EZH2 MECHANISM of ACtion FOLLICULAR LYMPHOMA (FL), DIFFUSE LARGE B-CELL LYMPH

  7. Slide 7: Advancing Tazemetostat for the Treatment of Non-Hodgkin Lymphoma

    Slide 7: Advancing Tazemetostat for the Treatment of Non-Hodgkin Lymphoma

    Evaluating multiple NHL subtypes (n=270) Complete phase 2 Enrollment in 2018 Premier collaborations enhance recruitment efforts Promising interim Activity, particularly in FL with EZH2 mutations1 Durable objective responses in both FL populations Evolving responses in FL wild-type and DLBCL with EZH

  8. Slide 8: Follicular Lymphoma: An Incurable Disease Today

    Slide 8: Follicular Lymphoma: An Incurable Disease Today

    Diagnosis: ~20% of patients have an EZH2 mutation1 ~40,000 patients treated in U.S. & EU5 annually2 FOLLICULAR LYMPHOMA: AN INCURABLE DISEASE TODAY Morin, R. Nat Genet. 2010 Decision Resources 2017 1st-line chemo: ~90% get systemic therapy: rituximab-based combo chemo3 TYPICAL LIFESPAN OF 7-10 YEARS

  9. Slide 9: Positive Interim Phase 2 Efficacy Data in EZH2 Mutation and Wild-Type FL

    Slide 9: Positive Interim Phase 2 Efficacy Data in EZH2 Mutation and Wild-Type FL

    POSITIVE INTERIM PHASE 2 EFFICACY DATA IN BOTH EZH2 MUTATION AND WILD-TYPE FL MEANINGFUL INTERIM EFFICACY DATA >50% patients refractory to last treatment 92% ORR in EZH2 mutation patients; 8% stable disease 26% ORR in wild-type EZH2 patients; 22% stable disease 75% of patients experienced reduction

  10. Slide 10: Regulatory Engagement Underway: Advancing Tazemetostat Broadly for FL

    Slide 10: Regulatory Engagement Underway: Advancing Tazemetostat Broadly for FL

    REGULATORY engagement UNDERWAY Advancing Tazemetostat BROADLY FOR fl Positive recent interaction with FDA on tazemetostat registration strategy for FL Fast Track Designation granted, regardless of EZH2 mutational status Phase 2 enrollment to finish in 2018 FL combination study to begin 2H 2018; desi

  11. Slide 11: Diffuse Large B-Cell Lymphoma: Multiple Lines of Treatment

    Slide 11: Diffuse Large B-Cell Lymphoma: Multiple Lines of Treatment

    DIFFUSE LARGE B-CELL LYMPHOMA: MULTIPLE LINES OF TREATMENT ~80,000 patients treated in U.S. and EU5 annually3 Diagnosis1: 40% GCB | 45% non-GCB (ABC) | 15% unclassified 20% w/ EZH2 mutation2 80% wild-type EZH2 RELAPSED/REFRACTORY ~45% relapse or become refractory to standard-of-care1,4: rituximab-ba

  12. Slide 12: Tazemetostat Interim Activity in DLBCL Patients with EZH2 Mutations

    Slide 12: Tazemetostat Interim Activity in DLBCL Patients with EZH2 Mutations

    TAZEMETOSTAT INTERIM ACTIVITY IN DLBCL PATIENTS WITH EZH2 MUTATIONS Highly refractory population Evolving 29% ORR in EZH2 mutation patients 69% experienced reduction in tumor burden Responses observed between 1 and 12 months 3 initial responders experienced clinical benefit for >1 year Phase 2 enrol

  13. Slide 13: Exploring DLBCL Treatment Opportunity Through Combinations

    Slide 13: Exploring DLBCL Treatment Opportunity Through Combinations

    DIRECT DEPENDENCE ON EZH2 FUNCTION MONOTHERAPY TARGETED AGENT COMBO APPROACHES I/O COMBO APPROACHES B-CELL MATURATION TUMOR & IMMUNE PRIMING EXPLORING DLBCL TREATMENT OPPORTUNITY THROUGH COMBINATIONS STEROID: preclinical synergy with prednisolone Enrolling as a separate cohort in the ongoing Phase 2

  14. Slide 14: Potential to Enhance Checkpoint Inhibition Through Combination

    Slide 14: Potential to Enhance Checkpoint Inhibition Through Combination

    EXPANDING TAZEMETOSTAT’S REACH: POTENTIAL TO ENHANCE CHECKPOINT INHIBITION THROUGH COMBINATION Graphic source: Chen and Mellman, Immunity 2013 EVIDENCE FOR EZH2 REGULATION SIGNIFICANT PRECLINICAL RATIONALE EZH2 inhibition may enhance immune system’s ability to fight cancer through direct effects on

  15. Slide 15: Epithelioid Sarcoma: Median Survival of Only ~30 Months

    Slide 15: Epithelioid Sarcoma: Median Survival of Only ~30 Months

    EPITHELIOID SARCOMA: MEDIAN SURVIVAL OF ONLY ~30 MONTHS1 RARE AND DEVASTATING SARCOMA ~600 ES patients in U.S. & EU51; (1% of all soft tissue sarcomas2) surgery 75% diagnosed with local or regional ES; treated with surgical resection + RT + CT 65% will recur with advanced disease Systemic treatment

  16. Slide 16: Clinically Meaningful Activity in Patients with Epithelioid Sarcoma

    Slide 16: Clinically Meaningful Activity in Patients with Epithelioid Sarcoma

    CLINICALLY MEANINGFUL ACTIVITY IN patients with EPITHELIOID SARCOMA Phase 2 Patients Phase 1 Patients Response ES (n=31) DCR, n (%) Objective response (confirmed) Stable disease ≥32 weeks 10 (32) 4 (13) 6 (19) Best overall response, n (%) Complete response Partial response (confirmed) Ongoing study

  17. Slide 17: Preparing for First Tazemetostat NDA

    Slide 17: Preparing for First Tazemetostat NDA

    Preparing for FIRST TAZEMETOSTAT NDA Pathway toward submission for accelerated approval for treatment of epithelioid sarcoma Enrollment completed in epithelioid sarcoma expansion cohort 60-patient cohort expected to form basis for regulatory submission Updated data at medical meeting in 2H 2018 TARG

  18. Slide 18: Exploring Additional INI1-Negative Tumors

    Slide 18: Exploring Additional INI1-Negative Tumors

    EXPLORING ADDITIONAL INI1-NEGATIVE TUMORS: MOLECULARLY DEFINED TUMORS WITH NO TARGETED TREATMENT OPTIONS Poor prognoses and high mortality rates U.S., EU, Japan annual incidence of ~2,000 patients (adults and children)1 Current standard-of-care is surgical resection with or without radiation Limited

  19. Slide 19: Tazemetostat Opportunity in Children with INI1-Negative Tumors

    Slide 19: Tazemetostat Opportunity in Children with INI1-Negative Tumors

    TAZEMETOSTAT OPPORTUNITY IN CHILDREN WITH INI1-NEGATIVE TUMORS Data from dose-escalation portion of study presented in oral session at 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Includes all patients at all dose levels (240 mg/m2 through 1200 mg/m2) Do

  20. Slide 20: Mesothelioma: Global Phase 2 Monotherapy Trial

    Slide 20: Mesothelioma: Global Phase 2 Monotherapy Trial

    Park EK Envi Health Perspectives 2011 Mahtab et al., Pathol. 2015 LaFave et al., Nature Medicine 2015 GLOBAL PHASE 2 MONOTHERAPY TRIAL UNDERWAY; ENROLLMENT COMPLETED Completed enrollment of relapsed/refractory mesothelioma patients (74 patients total) in 2017 Part 1: safety and PK in all-comer patie

  21. Slide 21: Tazemetostat: Pipeline-in-a-Product

    Slide 21: Tazemetostat: Pipeline-in-a-Product

    TAZEMETOSTAT: ‘PIPELINE-IN-A-PRODUCT’ WITH NEAR-TERM PATH TO REGISTRATION ACCELERATED APPROVAL OPPORTUNITIES in epithelioid sarcoma and FL MONOTHERAPY BENEFIT in relapsed/refractory treatment settings FAVORABLE SAFETY across clinical program ORAL DOSING provides ease-of-use for patients COMBINATION

  22. Slide 22: Leadership in Epigenetic Drug Discovery

    Slide 22: Leadership in Epigenetic Drug Discovery

    LEADERSHIP IN EPIGENTIC DRUG DISCOVERY FOCUS ON 3 GENE FAMILIES: HISTONE methyltransferases (HMTs) HISTONE ACETYLTRANSFERASES (HATs) HELICASES

  23. Slide 23: EZM8266: Novel G9a Inhibitor Advancing to Clinic

    Slide 23: EZM8266: Novel G9a Inhibitor Advancing to Clinic

    EZM8266: potent, orally available inhibitor of G9a (EHMT2) Inhibition of G9a shown to increase levels of fetal hemoglobin Elevation of fetal hemoglobin (normally silenced after birth) has disease-modifying potential for β-globinopathies, including sickle cell disease Encouraging preclinical activity

  24. Slide 24: Financially Strong to Support Significant Pipeline Advancements

    Slide 24: Financially Strong to Support Significant Pipeline Advancements

    FINANCIALLY STRONG TO SUPPORT SIGNIFICANT PIPELINE ADVANCEMENTS $218 MM IN NON-EQUITY FUNDING THROUGH STRATEGIC COLLABORATIONS 1. As of 9/30/17. 69.2M shares outstanding as of 9/30/17 $307.2 MM in cash and equivalents1 NO DEBT RUNWAY INTO AT LEAST 3Q 2019

  25. Slide 25: 2018 Roadmap: A Year of Clinical and Regulatory Milestones

    Slide 25: 2018 Roadmap: A Year of Clinical and Regulatory Milestones

    2018 ROADMAP: A YEAR OF CLINCAL AND REGULATORY MILESTONES 2018 FOLLICULAR LYMPHOMA Present updated monotherapy data and refined registration path Initiate combination study DLBCL Present updated monotherapy data and next development steps Present combination data SICKLE CELL DISEASE Complete IND-ena

  26. Slide 26: Pioneering the Development of Epigenetic Medicines

    Slide 26: Pioneering the Development of Epigenetic Medicines

    PIONEERING THE DEVELOPMENT OF EPIGENETIC MEDICINES TAZEMETOSTAT POSITIVE DATA IN SOLID TUMORS AND BLOOD CANCERS MULTIPLE TAZEMETOSTAT ACCELERATED APPROVAL OPPORTUNITIES FIRST NDA SUBMISSION TARGETED FOR 2H 2018 BROAD PIPELINE ADDRESSING NOVEL EPIGENETIC TARGETS FINANCIALLY STRONG EXPERIENCED LEADERS

Source: SEC EDGAR · 8-K filed Jan 8, 2018

More decks from Epizyme Inc